Ataraxis testing
Diagnostic TestAtaraxis AI's digital pathology-based artificial intelligence (AI) testing, ordered as part of routine clinical care.
NCT Number: NCT07706842
The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will link Ataraxis test results with short- and long-term patient outcomes to evaluate the real-world performance and clinical utility of Ataraxis tests. The ARC Registry utilizes an adaptable design, where additional Sponsor-led analyses and investigator-initiated ancillary studies can be added after the initial study is opened.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
The Ataraxis Real-World Clinical Outcomes (ARC) registry is a prospective, multi-site, non-interventional, observational registry designed to capture short- and long-term clinical outcomes of patients who undergo Ataraxis testing as part of routine clinical care. Ataraxis tests generate prognostic and predictive scores from digitized hematoxylin and eosin (H&E)-stained pathology slides and baseline clinical variables. Treatment is at the discretion of the treating physician in accordance with standard of care, and participation in the registry does not change or influence treatment selection.
Following enrollment, clinical data will be collected at multiple time points for up to 10 years. Data will be captured in Ataraxis AI's Portal.
Enrollment is planned over approximately two years, with follow-up extending up to 10 years per participant. Approximately 1,000 participants will be enrolled across participating U.S. sites.
Objectives:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ataraxis AI's digital pathology-based artificial intelligence (AI) testing, ordered as part of routine clinical care.
Time frame: 10 years
Establish a prospective, multi-site registry of patients receiving Ataraxis tests, linking results with clinical outcomes to evaluate the real-world prognostic and predictive performance and clinical utility of Ataraxis tests.
Time frame: 10 years
Evaluate the performance and clinical utility of Ataraxis tests across diverse patient populations, including across molecular subtypes, treatment regimens, and demographic and geographic strata, in real-world clinical practice.
Time frame: 10 years
Leverage the shared registry infrastructure to support downstream independent research by contributing site-investigators.
Contact information is provided by the study sponsor or research team.
Ataraxis AI, Inc.
Industry
Ataraxis Real-World Clinical Outcomes: A Prospective, Multi-Site, Observational Registry Linking AI-Based Pathology Scores With Short- and Long-Term Outcomes
Acronym: ARC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06753513
Malignant Tumors, Neoplasms
Hangzhou, Zhejiang, China
View Trial DetailsNCT05164016
Cancer, Cellular Therapy
Memphis, Tennessee, United States
View Trial DetailsNCT06911489
Solid Tumor Malignancy
Shanghai, China
View Trial DetailsNCT06985368
Solid Tumor Malignancy
Beijing, Beijing Municipality, China
View Trial Details